Drug Profile

Emiplacel - Pluri

Alternative Names: Allogeneic ex-vivo expanded placental adherent stromal cells; PLacental eXpanded cells; PLX PAD; PLX-PAD cell therapy

Latest Information Update: 12 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pluristem Therapeutics
Developer Pluri; Tel-Aviv Ichilov Medical Center
Class Ischaemic heart disorder therapies; Mesenchymal stem cell therapies; Stem cell therapies; Vascular disorder therapies
Mechanism of Action Cell differentiation modulators; Cell replacements; Dendritic cell modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Preeclampsia; Thromboangiitis obliterans
New Molecular Entity No

Phase III Chronic limb-threatening ischemia; Muscle injury
Phase II Intermittent claudication; SARS-CoV-2 acute respiratory disease
Phase I/II Graft-versus-host disease
No development reported Duchenne muscular dystrophy; Ischaemic heart disorders; Preeclampsia; Pulmonary arterial hypertension; Tendon injuries; Thromboangiitis obliterans

08 Apr 2024 Pluri has patent protection for System and Methods for Immune Cells Expansion and Activation in Large Scale in the US
06 Sep 2023 Pluristem completes a phase III trial for Muscle injury (In the elderly, In adults, In neonates, In infants, In children, In adolescents) in USA, Bulgaria, Denmark, Germany, United Kingdom and Israel (IM) (NCT03451916)
07 Jun 2023 Pluristem terminates a phase II trial in SARS-COV-2 acute respiratory disease in USA (IM) due to the decision to bring the study to early clinical readout came in response to COVID-19's evolution as a disease, and the significant changes in the standard of care, leading to an increase in the severity of conditions of the intubated patients (NCT04389450)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com